Clinical Trials Browser

Melanoma × palbociclib × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT04720768 2024-01-05

CELEBRATE

Phase 1/2 Unknown

Melanoma, Neoplasm Metastasis

NCT01037790 2021-03-11

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Phase 2 Completed

304 enrolled 12 charts

BreastDermatologicGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Phase 1 Completed

Melanoma, Neoplasms

NCT03454919 2018-03-06

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Phase 2 Unknown

Melanoma

NCT02202200 2016-04-18

OPTIMUM

Phase 1/2 Unknown

Melanoma